Resources

Presentations and videos

Minimal residual disease in Myeloma Session 1
Minimal residual disease in Myeloma Session 2
Improving Survival in Multiple Myeloma
What’s new in Myeloma Treatment: a New Zealand Perspective
CAR T-cell Therapy: a New Frontier in Blood Cancer Treatment
Four Decades of Myeloma – Ken Romeril

Research and articles

Multiple Myeloma Research Review

Highlights include: • Once-weekly vs twice weekly carfilzomib for newly diagnosed MM • Negative trials for pembrolizumab in treatment naive and relapsed/refractory MM • Daratumumab plus dexamethasone in triple refractory MM Download...
Continue Reading

Impact of age, sex, ethnicity, socio-economic deprivation and novel pharmaceuticals on the overall survival of patients with multiple myeloma in New Zealand

The impact of age, ethnicity and socio-economic deprivation in the era of novel anti-myeloma agents is unclear. Using linked national data from New Zealand, we evaluated the incidence, prevalence and...
Continue Reading

Multiple Myeloma Research Review

Highlights include: • Increased novel agent access in NZ improved MM survival • Pomalidomide-based regimens for relapsed/refractory MM • Daratumumab, lenalidomide + dexamethasone for untreated myeloma Download here: Multiple Myeloma...
Continue Reading

The Burden of Myeloma Reports

The Burden of Multiple Myeloma: A study of the human and economic costs of myeloma in New Zealand
The Way Forward

 

Patients’ Perspectives

Development and diagnosis of multiple myeloma

Multiple myeloma treatment options and pathways